Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status?

The treatment of multiple myeloma has changed significantly in the last decade. Antibody-drug conjugates, T-cell immunotherapies including bispecific T-cell engaging antibodies and chimeric antigen receptor T-cell therapies, have shown remarkable res…

Preview only. Read the full abstract at the source